Welcome to the ADC Pharmacokinetics & Clinical Pharmacology Summit: Uniting ADC PK, PD, ADME & Clinical Pharmacology Experts
As ADC approvals grow and pipelines expand, dose selection has become one of the field’s biggest challenges, and Project Optimus has resulted in pushing developers to move beyond maximum tolerated dose and define regimens that truly balance safety and efficacy.
Increasingly complex ADC design only amplifies these challenges; bispecifics, dual payloads, and combination regimens are all contributing to increased scrutiny and effect on PKPD profiles and clinical pharmacology.
The 2nd ADC Pharmacokinetics & Clinical Pharmacology Summit brings together experts in PKPD, bioanalysis, pharmacometrics, and clinical pharmacology to share novel data and real-world case studies. Collaborate with 40+ colleagues across biotech, pharma, and academia in a focused environment to exchange knowledge, refine dose strategies, and accelerate the delivery of safe, effective ADCs to patients.
"
Dose optimization is an integral aspect for any successful development program, and most importantly for patients. This event fosters communications among stakeholders about successful and practical dose optimization strategies.
"
2025 Speaker,
Global Clinical Pharmacology Lead
Download the Full Event Guide to Discover:
- Hands-on workshops exploring the latest in novel conjugates and combination therapies
- Insider talks from AstraZeneca, Daiichi Sankyo, Genentech, and other industry leaders
- Interactive roundtables where your voice drives the discussion
- Premium networking opportunities to connect with the people shaping ADC innovation
Testimonials:
"Â
The high quality of the presentation and the opportunity to openly discuss with colleagues from different companies. Very insightful discussion
"
Past Attendee,
Associate Director, Clinical Pharmacology & Pharmacometrics
"
It was great to have a meeting dedicated to ADC Clinical Pharmacology and PK considerations. The topics related to these functions often get lost in the mix at larger meetings. The number of attendees was conducive to easy communication and organic exchange of ideas.
"
Past Attendee,
Associate Director
"
Met and discussed with experts in the field. I had some specific questions in mind and got answers from conversations with other experts
"
Past Attendee,
Senior Director, Head of PharmacometricsÂ
Preview of the Speaker Faculty:
Salaheldin Hamed
Director - Clinical Pharmacology, Cell Therapy, Biologics & Oncology
Astellas Pharma
Attending Companies Include:
Explore Related Events:
Improving Prediction & Translation of ADC Toxicities to Drive More Tolerable ADCs Successfully Into & Through Clinical Development
Maximise the Therapeutic Index & Accelerate Your ADC Journey from Concept to Approved Therapy
Moving the Needle Through Innovation in ADC Chemistry, Improving Patient Stratification for Clinical Trials & Optimizing Manufacturing Efficiency to Progress ADCs to Standard of Care Oncology Treatments
